DDrare: Database of Drug Development for Rare Diseases

Rituximab (mabthera® or rituxan®). (DrugBank: Rituximab)

2 diseases

ID	Disease name (Link within this page)	Number of trials
35	Pemphigus	1
61	Autoimmune hemolytic anemia	1

35. Pemphigus [ 87 clinical trials, 114 drugs, (DrugBank: 37 drugs), 17 drug target genes, 158 drug target pathways]

Searched query = "Pemphigus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 87 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00960713 (ClinicalTrials.gov)	June 2009	16/7/2009	The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders	The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders	Pemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;Cryoglobulinemia	Drug: Rituximab (MABTHERA® or RITUXAN®).	University Hospital, Toulouse	NULL	Completed	18 Years	N/A	Both	35	N/A	France

61. Autoimmune hemolytic anemia [ 90 clinical trials, 72 drugs, (DrugBank: 23 drugs), 19 drug target genes, 147 drug target pathways]

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 90 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00960713 (ClinicalTrials.gov)	June 2009	16/7/2009	The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders	The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders	Pemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;Cryoglobulinemia	Drug: Rituximab (MABTHERA® or RITUXAN®).	University Hospital, Toulouse	NULL	Completed	18 Years	N/A	Both	35	N/A	France